📊 ANAB Key Takeaways
Is Anaptysbio, Inc. (ANAB) a Good Investment?
AnaptysBio demonstrates exceptional revenue growth of 157% YoY with strong liquidity and positive free cash flow, indicating successful commercialization of its pharmaceutical portfolio. However, the company remains unprofitable with negative net margin of -5.6% and declining equity value, raising concerns about cost structure and path to sustainable profitability despite impressive top-line growth.
AnaptysBio shows sharply improved fundamentals, with revenue up 157% year over year, positive operating income, and positive free cash flow, while maintaining a very large cash balance and no debt. However, the business still posted a net loss, returns on equity and assets remain negative, and the quality and durability of revenue in a biotech model can be uneven, which supports a balanced rather than aggressive stance.
Why Buy Anaptysbio, Inc. Stock? ANAB Key Strengths
- Exceptional revenue growth of 157% YoY indicating strong market demand and successful product commercialization
- Fortress balance sheet with $238.2M cash and 9.07x current ratio providing substantial financial flexibility
- Positive free cash flow generation of $19.6M with 8.4% FCF margin despite negative net income, suggesting operational efficiency
- Improving profitability trend with net loss narrowed 90.9% YoY, showing trajectory toward breakeven
- Strong top-line growth with revenue reaching $234.60M and operating margin of 20.4%
- Excellent liquidity profile with $238.20M in cash, current ratio of 9.07x, and no meaningful leverage
- Positive operating cash flow and free cash flow indicate improved cash generation
ANAB Stock Risks: Anaptysbio, Inc. Investment Risks
- Company remains unprofitable with -$13.2M net income and negative ROE (-35.6%) and ROA (-3.6%) indicating shareholder value destruction
- Significant divergence between operating income ($47.9M positive) and net income (-$13.2M negative) suggests material non-operating expenses or charges requiring clarification
- Stockholders' equity eroded to $37.2M against $364.4M total assets, indicating accumulated losses have substantially diminished equity base
- High insider trading activity with 26 Form 4 filings in 90 days warrants monitoring for potential information asymmetry concerns
- Net income remains negative despite operating profitability, showing earnings quality is still mixed
- Very low stockholders' equity of $37.21M relative to assets suggests a thin capital base
- Revenue growth may be less durable if driven by milestone or collaboration payments typical in biotech
Key Metrics to Watch
- Net income trend toward profitability - critical to confirm sustainability of operations
- Gross margin percentage once disclosed - essential to assess underlying unit economics and pricing power
- Operating cash flow sustainability and FCF conversion ratio - verify whether positive cash generation persists
- Stockholders' equity trajectory - monitor whether continued losses further erode capital base
- Operating expense growth rate relative to revenue growth - determine if cost structure is scalable
- Sustainability of revenue and operating margin across future periods
- Net income and operating cash flow consistency
Anaptysbio, Inc. (ANAB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.07x current ratio provides a solid financial cushion.
ANAB Profit Margin, ROE & Profitability Analysis
ANAB vs Healthcare Sector: How Anaptysbio, Inc. Compares
How Anaptysbio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Anaptysbio, Inc. Stock Overvalued? ANAB Valuation Analysis 2026
Based on fundamental analysis, Anaptysbio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Anaptysbio, Inc. Balance Sheet: ANAB Debt, Cash & Liquidity
ANAB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Anaptysbio, Inc.'s revenue has grown significantly by 213% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.08 indicates the company is currently unprofitable.
ANAB Revenue Growth, EPS Growth & YoY Performance
ANAB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $30.0M | $15.1M | $0.52 |
| Q2 2025 | $11.0M | -$38.6M | $-1.34 |
| Q1 2025 | $7.2M | -$39.3M | $-1.28 |
| Q3 2024 | $3.3M | -$32.9M | $-1.14 |
| Q2 2024 | $3.5M | -$39.8M | $-1.50 |
| Q1 2024 | $1.4M | -$43.9M | $-1.58 |
| Q3 2023 | $1.3M | -$32.6M | $-1.18 |
| Q2 2023 | $1.2M | -$32.6M | $-1.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Anaptysbio, Inc. Dividends, Buybacks & Capital Allocation
ANAB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Anaptysbio, Inc. (CIK: 0001370053)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANAB
What is the AI rating for ANAB?
Anaptysbio, Inc. (ANAB) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 67% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANAB's key strengths?
Claude: Exceptional revenue growth of 157% YoY indicating strong market demand and successful product commercialization. Fortress balance sheet with $238.2M cash and 9.07x current ratio providing substantial financial flexibility. ChatGPT: Strong top-line growth with revenue reaching $234.60M and operating margin of 20.4%. Excellent liquidity profile with $238.20M in cash, current ratio of 9.07x, and no meaningful leverage.
What are the risks of investing in ANAB?
Claude: Company remains unprofitable with -$13.2M net income and negative ROE (-35.6%) and ROA (-3.6%) indicating shareholder value destruction. Significant divergence between operating income ($47.9M positive) and net income (-$13.2M negative) suggests material non-operating expenses or charges requiring clarification. ChatGPT: Net income remains negative despite operating profitability, showing earnings quality is still mixed. Very low stockholders' equity of $37.21M relative to assets suggests a thin capital base.
What is ANAB's revenue and growth?
Anaptysbio, Inc. reported revenue of $234.6M.
Does ANAB pay dividends?
Anaptysbio, Inc. does not currently pay dividends.
Where can I find ANAB SEC filings?
Official SEC filings for Anaptysbio, Inc. (CIK: 0001370053) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANAB's EPS?
Anaptysbio, Inc. has a diluted EPS of $-0.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ANAB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Anaptysbio, Inc. has a HOLD rating with 67% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ANAB stock overvalued or undervalued?
Valuation metrics for ANAB: ROE of -35.6% (sector avg: 15%), net margin of -5.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ANAB stock in 2026?
Our dual AI analysis gives Anaptysbio, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANAB's free cash flow?
Anaptysbio, Inc.'s operating cash flow is $19.7M, with capital expenditures of $87.0K. FCF margin is 8.4%.
How does ANAB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5.6% (avg: 12%), ROE -35.6% (avg: 15%), current ratio 9.07 (avg: 2).